BioSpace News Archive

Propanc Biopharma, Inc. today announced that a Joint Research Collaboration Agreement has been established with the Universities of Jaén and Granada, Spain.

MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), announced today the publication of data in the Journal of Gerontology: Biological Sciences (JGBS) from a pre-clinical study of MYMD-1® demonstrating four-fold greater improvements than rapamycin in delaying aging and extending the life of mice who began treatment at the human equivalent of 60 years of age.

Cassava Sciences, Inc. today announced financial results for the second quarter ended June 30, 2022, a mid-year corporate update, and interim clinical results of an open-label study with simufilam.

Genixus, a pharmaceutical company focused on transforming acute and critical care medicines, today announced that it has received both federal registration and state licensing to begin commercial production of its new KinetiX™ RTA Platform brand of pre-filled syringes.

LG Chem recently announced that the Company has submitted an IND application to the US FDA for its first independent global Phase 3 clinical trial of its new gout drug ‘Tigulixostat’ (clinical program name: EURELIA_1 Study).

According to Vision Research Report, the Europe hyperspectral imaging market was valued at USD 2.94 billion in 2021 and it is predicted to surpass around USD 7.52 billion by 2030 with a CAGR of 11.0% from 2022 to 2030.

According to Report Study, the global HIV clinical trials market was estimated at USD 1.25 billion in 2021 and it is expected to surpass around USD 2.42 billion by 2030, poised to grow at a CAGR of 7.62% from 2022 to 2030.

ECRI, an independent, nonprofit health services organization that provides technology solutions and evidence-based guidance to healthcare decision makers worldwide, announces the winners of its eleventh annual Healthcare Supply Chain Excellence Award.

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today presented data showing the use of novel antibodies targeting hyperphosphorylated forms of tau.

Catalyst Biosciences, Inc. announced that leading proxy advisory firms Institutional Shareholder Services Inc. and Glass Lewis have recommended that Catalyst stockholders vote FOR all of the Company’s nominees on the WHITE proxy card in advance of Catalyst’s upcoming 2022 Annual Meeting of Stockholders, scheduled to be held on August 15, 2022.